Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Articles

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival.

FDA Approves Sotorasib Plus Panitumumab for KRAS G12C-Mutated Metastatic CRC

®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

Small cell lung cancer (SCLC) is strongly linked to smoking, with about 80% of lung cancer deaths attributed to tobacco use.

FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases

Despite the availability of several noninvasive tests for colorectal cancer, prioritizing blood-based tests may result in higher costs and worse population-level outcomes. 

Prioritizing Blood-Based Colorectal Cancer Tests May Lead to Higher Costs, Worse Outcomes

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.

High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Metabolic dysfunction-associated steatohepatitis (MASH)

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Enhancing Patient Care in DLBCL and FL:  Insights on Industry-Provided Patient Support Services 

Video Series

Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

Video content above is prompted by the following:

Please describe the impact that a diagnosis of diffuse large B-cell lymphoma or follicular lymphoma has on patients physically and emotionally and how this influences their journey through treatment.

Videos

Panelists discuss how industry-provided patient support services can address the physical, emotional, and practical challenges faced by patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), from diagnosis through treatment and beyond.

Panelists discuss how a diagnosis of diffuse large B-cell lymphoma or follicular lymphoma affects patients physically and emotionally and how these challenges shape their treatment journey and overall care.

Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and psychological support strategies employed to help patients navigate their lymphoma journey.

Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

Panelists discuss how they assess the individual support needs of patients diagnosed with diffuse large B-cell lymphoma or follicular lymphoma and describe an ideal model for industry-provided support services for these patients.

Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP: 1.Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP: 2.Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

EP: 3.Tailored Support: The Role of Industry-Provided Services in Lymphoma Care